360 related articles for article (PubMed ID: 11464868)
41. Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.
Van Roy N; Laureys G; Van Gele M; Opdenakker G; Miura R; van der Drift P; Chan A; Versteeg R; Speleman F
Eur J Cancer; 1997 Oct; 33(12):1974-8. PubMed ID: 9516836
[TBL] [Abstract][Full Text] [Related]
42. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
43. Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain.
Schleiermacher G; Bourdeaut F; Combaret V; Picrron G; Raynal V; Aurias A; Ribeiro A; Janoueix-Lerosey I; Delattre O
Oncogene; 2005 May; 24(20):3377-84. PubMed ID: 15735707
[TBL] [Abstract][Full Text] [Related]
44. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma.
Caron H
Med Pediatr Oncol; 1995 Apr; 24(4):215-21. PubMed ID: 7700165
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content.
Piqueras M; Navarro S; Cañete A; Castel V; Noguera R
Histopathology; 2011 Jul; 59(1):22-30. PubMed ID: 21668478
[TBL] [Abstract][Full Text] [Related]
46. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.
Theissen J; Oberthuer A; Hombach A; Volland R; Hertwig F; Fischer M; Spitz R; Zapatka M; Brors B; Ortmann M; Simon T; Hero B; Berthold F
Genes Chromosomes Cancer; 2014 Aug; 53(8):639-49. PubMed ID: 24737690
[TBL] [Abstract][Full Text] [Related]
47. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R; Hero B; Simon T; Berthold F
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
[TBL] [Abstract][Full Text] [Related]
48. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
49. Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.
Łastowska M; Chung YJ; Cheng Ching N; Haber M; Norris MD; Kees UR; Pearson AD; Jackson MS
Genes Chromosomes Cancer; 2004 Jun; 40(2):158-63. PubMed ID: 15101050
[TBL] [Abstract][Full Text] [Related]
50. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
51. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
[TBL] [Abstract][Full Text] [Related]
52. Comparative genomic hybridization (CGH) analysis of neuroblastomas--an important methodological approach in paediatric tumour pathology.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Boecker W; Lampert F; Stoerkel S
J Pathol; 1997 Apr; 181(4):394-400. PubMed ID: 9196436
[TBL] [Abstract][Full Text] [Related]
53. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
Ohtsu K; Hiyama E; Ichikawa T; Matsuura Y; Yokoyama T
Clin Cancer Res; 1997 Jul; 3(7):1221-8. PubMed ID: 9815803
[TBL] [Abstract][Full Text] [Related]
54. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
[TBL] [Abstract][Full Text] [Related]
55. Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines.
Lastowska M; Van Roy N; Bown N; Speleman F; Lunec J; Strachan T; Pearson AD; Jackson MS
Genes Chromosomes Cancer; 1998 Oct; 23(2):116-22. PubMed ID: 9739014
[TBL] [Abstract][Full Text] [Related]
56. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.
Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I
Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439
[TBL] [Abstract][Full Text] [Related]
57. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G; Michon J; Huon I; d'Enghien CD; Klijanienko J; Brisse H; Ribeiro A; Mosseri V; Rubie H; Munzer C; Thomas C; Valteau-Couanet D; Auvrignon A; Plantaz D; Delattre O; Couturier J;
Br J Cancer; 2007 Jul; 97(2):238-46. PubMed ID: 17579628
[TBL] [Abstract][Full Text] [Related]
58. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.
Godfried MB; Veenstra M; v Sluis P; Boon K; v Asperen R; Hermus MC; v Schaik BD; Voûte TP; Schwab M; Versteeg R; Caron HN
Oncogene; 2002 Mar; 21(13):2097-101. PubMed ID: 11960382
[TBL] [Abstract][Full Text] [Related]
59. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
60. Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping.
Stark B; Jeison M; Bar-Am I; Glaser-Gabay L; Mardoukh J; Luria D; Feinmesser M; Goshen Y; Stein J; Abramov A; Zaizov R; Yaniv I
Genes Chromosomes Cancer; 2002 Jul; 34(3):313-24. PubMed ID: 12007192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
